KLRA1P and systemic lupus erythematosus: In the case of SLE, as there is currently no drug specifically designed to increase Helios levels in target cells, one potential treatment for this pathology could be the injection of therapeutical cells that either express enhanced levels of Helios (CD8+ Ly49+ iTreg cells) or promote its expression (tolDCs).